Zachary Segal, MD
Ophthalmology · South Miami, FLNPI 1881630887
Payments from drug & device makers
Across 346 payments — averaging $3166.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$205K
- AbbVie$201K
- Roche TCRC, Inc.$172K
- Novartis$166K
- Regeneron$152K
- Eyepoint US, Inc.$105K
- plus $94K from 25 others
Across 1 payment — averaging $10,751 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$11K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 7 | $205,017 |
| AbbVie(2 entities) | 169 | $201,159 |
| Roche TCRC, Inc. | 13 | $172,174 |
| Novartis | 14 | $165,995 |
| Regeneron | 18 | $152,296 |
| Eyepoint US, Inc. | 8 | $105,030 |
| Sun Pharmaceutical Industries Inc. | 9 | $38,731 |
| Ocular Therapeutix, Inc. | 13 | $25,510 |
| Janssen Research & Development, LLC | 3 | $13,386 |
| AstraZeneca | 2 | $6,785 |
| Hexal AG | 1 | $4,500 |
| Boehringer Ingelheim International GmbH | 19 | $1,569 |
| Alcon | 19 | $924 |
| NEW World Medical,inc. | 6 | $760 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $372 |
| Bausch & Lomb Americas Inc. | 4 | $267 |
| Mallinckrodt Hospital Products Inc. | 13 | $247 |
| Boehringer Ingelheim | 1 | $150 |
| Harrow Eye, LLC | 5 | $144 |
| Genentech USA, Inc. | 6 | $107 |
| Biotissue Holdings Inc. | 1 | $58 |
| Glaukos Corporation | 2 | $52 |
| Sight Sciences, Inc. | 1 | $51 |
| Astellas Pharma US Inc | 1 | $32 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Eyevance Pharmaceuticals LLC | 1 | $26 |
| Dompe US, Inc. | 1 | $25 |
| Ivantis, Inc | 1 | $23 |
| Alimera Sciences, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$1,095,462 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in South Miami
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.